CPHIHIGH SIGNALFINANCIAL10-K

CPHI shows substantial improvement in gross profit margins while facing significant liquidity pressure from declining cash and rising current liabilities.

The company's operating performance improved meaningfully with gross losses substantially reduced, suggesting better cost management or pricing strategies. However, the sharp decline in cash reserves combined with increased current liabilities creates immediate liquidity concerns that investors should monitor closely.

Comparing 2026-04-01 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

CPHI demonstrated notable operational improvements with gross profit substantially recovering and net losses reduced by approximately one-third. However, the company's financial position deteriorated with cash declining 42.5% to just $345K while current liabilities increased 47.5% to $7.4M, creating a significant liquidity gap. The combination of improved operational metrics but weakening balance sheet liquidity presents a mixed but concerning financial picture requiring immediate attention.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+93.4%
-$2.0M→-$132K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Capital Expenditure
Cash Flow
+54.4%
$38K→$59K

Capital expenditure jumped 54.4% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
+47.5%
$5.0M→$7.4M

Current liabilities surged 47.5% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-42.5%
$600K→$345K

Cash declined 42.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+32.7%
-$4.7M→-$3.2M

Net income grew 32.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+29.4%
-$4.6M→-$3.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Inventory
Balance Sheet
-28.5%
$2.3M→$1.6M

Inventory reduced 28.5% — lean inventory management or demand outpacing supply.

Current Assets
Balance Sheet
-28.3%
$3.3M→$2.3M

Current assets declined 28.3% — monitor working capital adequacy and short-term liquidity.

Total Debt
Balance Sheet
+21.9%
$4.3M→$5.2M

Debt rose 21.9% — additional borrowing for investment or operations; monitor coverage ratios.

Total Liabilities
Balance Sheet
+15.7%
$7.1M→$8.3M

Liabilities increased 15.7% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-31
ADDED
The number of outstanding shares of the registrant s common stock on March 25, 2026, was 40,522,002 .
69 SIGNATURES 70 EXHIBIT INDEX 71 FINANCIAL STATEMENTS F-1 i FORWARD-LOOKING STATEMENTS The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements .
2 Industry Background and Market Opportunities China s pharmaceutical industry is highly policy-driven, with policies such as generic drug consistency evaluation and centralized volume-based procurement (CP) exerting a significant impact on the market landscape.
According to the National Bureau of Statistics of China, in the first half of 2024, pharmaceutical enterprises above a designated size achieved operating income of RMB 1.47 trillion (approximately USD 205 billion), a year-on-year decrease of 1.4%, and profits of RMB 211.2 billion (approximately USD 29.5 billion), down 1.2% year on year.
Unlike Western markets, China s pharmaceutical sector features a large number of small and medium-sized manufacturers, low industrial concentration, and fierce competition over homogeneous products.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock on March 24, 2025, was 32,619,109 .
73 SIGNATURES 74 EXHIBIT INDEX 75 FINANCIAL STATEMENTS F-1 i FORWARD-LOOKING STATEMENTS The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements .
2 Industry Background and Market Opportunities China s pharmaceutical industry is heavily policy-driven.
Policies like the generic drug consistency evaluation and centralized volume-based procurement (CP) significantly shape the market.
According to the National Bureau of Statistics of China, in the first half of 2024, pharmaceutical enterprises above a designated size reported operating income of RMB 1.47 trillion (approximately $205 billion), a 1.4% year-on-year decline, and profits of RMB 211.2 billion (approximately $29.5 billion), down 1.2%.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →